Preparation and characterization of a monoclonal antibody against human B lymphocyte stimulator

Hybridoma

Volumn 25, Issue 2, 2006, Pages 80-85

  Sun, Jian ^a,b   Li, Yan ^b   Sun, Yingxun ^b   Yu, Ming ^b   Feng, Jiannan ^b   Shen, Beifen ^b  

^a TIANJIN UNIVERSITY   (China)

^b INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE STIMULATOR; COMPLEMENTARY DNA; MONOCLONAL ANTIBODY; NICKEL; PROTEIN A; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

AFFINITY CHROMATOGRAPHY; ANTIBODY PRODUCTION; ARTICLE; ASCITES; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CELL STRAIN U937; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; EXPRESSION VECTOR; FEMALE; HUMAN; HUMAN CELL; HYBRIDOMA; IMMUNIZATION; IMMUNOFLUORESCENCE; MOUSE; MULTIPLE MYELOMA; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RECOMBINANT PLASMID; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPLEEN CELL; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, MONOCLONAL; B-CELL ACTIVATING FACTOR; DNA, COMPLEMENTARY; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; HUMANS; HYBRIDOMAS; MEMBRANE PROTEINS; MICE; PLASMIDS; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR NECROSIS FACTOR-ALPHA; U937 CELLS;

ESCHERICHIA COLI; PROKARYOTA;

EID: 33646452781     PISSN: 15540014     EISSN: None     Source Type: Journal    
DOI: 10.1089/hyb.2006.25.80     Document Type: Article

References (24)

1. Moore PA, Belvedere O, Orr A, Fieri K, LaFleur DW, Feng P, Soppet D, Charters M, Gentz R, Parmelee D, Li Y, Galperina O, Giri J, Roschke V, Nardelli B, Carrell J, Sosnovtseva S, Greenfield W, Ruben SM, Olsen HS, Fikes J, and Hilbert DM: BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 1999;286:260-263.
2. Schneider P, MacKay F, Steiner V, Hofmann K, Bodmer JL, Holler N, Ambrose C, Lawton P, Bixler S, Acha-Orbea H, Valmori D, Romero P, Werner-Favre C, Zubler RH, Browning JL, and Tschopp J: BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 1999;189:1747-1756.
3. Shu HB, Hu WH, and Johnson H: TALL-1 is a novel member of the TNF family that is down-regulated by mitogens. J Leukoc Biol 1999;65:680-683.
4. Batten M, Groom J, Cachero TG, Qian F, Schneider P, Tschopp J, Browning JL, and Mackay F: BAFF mediates survival of peripheral immature B lymphocytes. J Exp Med 2000;192:1453-1465.
5. Schiemann B, Gommerman JL, Vora K, Cachero TG, Shulga-Morskaya S, Dobles M, Frew E, and Scott ML: An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science 2001;293:2111-2114.
6. Gross JA, Johnston J, Mudri S, Enselman R, Dillon SR, Madden K, Xu W, Parrish-Novak J, Foster D, Lofton-Day C, Moore M, Littau A, Grossman A, Haugen H, Foley K, Blumberg H, Harrison K, Kindsvogel W, and Clegg CH: TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 2000;404:995-999.
7. Thompson JS, Bixler SA, Qian F, Vora K, Scott ML, Cachero TG, Hession C, Schneider P, Sizing ID, Mullen C, Strauch K, Zafari M, Benjamin CD, Tschopp J, Browning JL, and Ambrose C: BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science 2001;293:2108-2111.
8. Claudio E, Brown K, Park S, Wang H, and Siebenlist U: BAFF-induced NEMO-independent processing of NF-kappa B2 in maturing B cells. Nat Immunol 2002;3:958-965.
9. Shu H and Johnson H: B cell maturation protein is a receptor for the tumor necrosis factor family member TALL-1. Proc Natl Acad Sci USA 2000;97:9156-9161.
10. Groom J, Kalled SL, Cutler AH, Olson C, Woodcock SA, Schneider P, Tschopp J, Cachero TG, Batten M, Wheway J, Mauri D, Cavill D, Gordon TP, Mackay CR, and Mackay F: Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjogren's syndrome. J Clin Invest 2002;109:59-68.
11. Cheema GS, Roschke V, Hilbert DM, and Stohl W: Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthrit Rheum 2001;44:1313-1319.
12. Khare SD, Sarosi I, Xia XZ, McCabe S, Miner K, Solovyev I, Hawkins N, Kelley M, Chang D, Van G, Ross L, Delaney J, Wang L, Lacey D, Boyle WJ, and Hsu H: Severe B cell hyperplasia and autoimmune diseases in TALL-1 transgenic mice. Proc Natl Acad Sci USA 2000;97:3370-3375.
13. Thien M, Phan TG, Gardam S, Amesbury M, Basten A, Mackay F, and Brink R: Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 2004;20:785-798.
14. He B, Chadburn A, Jou E, Schattner EJ, Knowles DM, and Cerutti A: Lymphoma B cells evade apoptosis through the TNF family members BAFF/BLyS and APRIL. J Immunol 2004;172:3268-3279.
15. Novak AJ, Darce JR, Arendt BK, Harder B, Henderson K, Kindsvogel W, Gross JA, Greipp PR, and Jelinek DF: Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood 2004;103:689-694.
16. Moreaux J, Legouffe E, Jourdan E, Quittet P, Rème T, Lugagne C, Moine P, Rossi JF, Klein B, and Tarte K: BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood 2004;103:3148-3157.
17. Novak AJ, Bram RJ, Kay NE, and Jelinek DF: Aberrant expression of B-lymphocyte stimulator by B chronic lymphocytic leukemia cells: a mechanism for survival. Blood 2002;100:2973-2979.
18. Kern C, Cornuel JF, Billard C, Tang R, Rouillard D, Stenou V, Defrance T, Ajchenbaum-Cymbalista F, Simonin PV, Feldblum S, and Kolb JP: Involvement of BAFF and APRIL in the resistance to apoptosis of B-CLL through an autocrine pathway. Blood 2004;103:679-688.
19. Qin W, Feng J, Zhang W, Li Y, and Shen B: A novel TNFα antagonizing peptide-Fc fusion protein designed based on CDRs of TNFα neutralizing monoclonal antibody. Biochem Biophys Res Commun 2004;322:1024-1028.
20. Sundstrom C and Nilsson K: Establishment and characterization of a human histiocytic lymphoma cell line (U937). Int J Cancer 1976;17:565-577.
21. Xie Z, Guo N, Yu M, Hu M, and Shen B: A new format of bis-pecific antibody: highly efficient heterodimerization, expression and tumor cell lysis. J Immunol Methods 2005;296:95-101.
22. Ramanujam M, Wang X, Huang W, Schiffer L, Grimaldi C, Akkerman A, Diamond B, Madaio MP, and Davidson A: Mechanism of action of transmembrane activator and calcium modulator ligand interactor-Ig in murine systemic lupus erythematosus. J Immunol 2004;173:3524-3534.
23. Wang H, Marsters SA, Baker T, Chan B, Lee WP, Fu L, Tumas D, Yan M, Dixit VM, Ashkenazi A, and Grewal IS: TACI-ligand interactions are required for T cell activation and collagen-induced arthritis in mice. Nat Immun 2001;2:632-637.
24. Lorenz HM and Kalden JR: Perspectives for TNF-α-targeting therapies. Arthritis Res 2002;4(suppl 3):S17-S24.